Cargando…
Insight into ECMO, mortality and ARDS: a nationwide analysis of 45,647 ECMO runs
BACKGROUND: Extracorporeal life support (ECLS) has become an integral part of modern intensive therapy. The choice of support mode depends largely on the indication. Patients with respiratory failure are predominantly treated with a venovenous (VV) approach. We hypothesized that mortality in Germany...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841040/ https://www.ncbi.nlm.nih.gov/pubmed/33509228 http://dx.doi.org/10.1186/s13054-021-03463-2 |
_version_ | 1783643712692158464 |
---|---|
author | Friedrichson, Benjamin Mutlak, Haitham Zacharowski, Kai Piekarski, Florian |
author_facet | Friedrichson, Benjamin Mutlak, Haitham Zacharowski, Kai Piekarski, Florian |
author_sort | Friedrichson, Benjamin |
collection | PubMed |
description | BACKGROUND: Extracorporeal life support (ECLS) has become an integral part of modern intensive therapy. The choice of support mode depends largely on the indication. Patients with respiratory failure are predominantly treated with a venovenous (VV) approach. We hypothesized that mortality in Germany in ECLS therapy did not differ from previously reported literature METHODS: Inpatient data from Germany from 2007 to 2018 provided by the Federal Statistical Office of Germany were analysed. The international statistical classification of diseases and related health problems codes (ICD) and process keys (OPS) for extracorporeal membrane oxygenation (ECMO) types, acute respiratory distress syndrome (ARDS) and hospital mortality were used. RESULTS: In total, 45,647 hospitalized patients treated with ECLS were analysed. In Germany, 231 hospitals provided ECLS therapy, with a median of 4 VV-ECMO and 9 VA-ECMO in 2018. Overall hospital mortality remained higher than predicted in comparison to the values reported in the literature. The number of VV-ECMO cases increased by 236% from 825 in 2007 to 2768 in 2018. ARDS was the main indication for VV-ECMO in only 33% of the patients in the past, but that proportion increased to 60% in 2018. VA-ECMO support is of minor importance in the treatment of ARDS in Germany. The age distribution of patients undergoing ECLS has shifted towards an older population. In 2018, the hospital mortality decreased in VV-ECMO patients and VV-ECMO patients with ARDS to 53.9% (n = 1493) and 54.4% (n = 926), respectively. CONCLUSIONS: ARDS is a severe disease with a high mortality rate despite ECLS therapy. Although endpoints and timing of the evaluations differed from those of the CESAR and EOLIA studies and the Extracorporeal Life Support Organization (ELSO) Registry, the reported mortality in these studies was lower than in the present analysis. Further prospective analyses are necessary to evaluate outcomes in ECMO therapy at the centre volume level. |
format | Online Article Text |
id | pubmed-7841040 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-78410402021-01-28 Insight into ECMO, mortality and ARDS: a nationwide analysis of 45,647 ECMO runs Friedrichson, Benjamin Mutlak, Haitham Zacharowski, Kai Piekarski, Florian Crit Care Research BACKGROUND: Extracorporeal life support (ECLS) has become an integral part of modern intensive therapy. The choice of support mode depends largely on the indication. Patients with respiratory failure are predominantly treated with a venovenous (VV) approach. We hypothesized that mortality in Germany in ECLS therapy did not differ from previously reported literature METHODS: Inpatient data from Germany from 2007 to 2018 provided by the Federal Statistical Office of Germany were analysed. The international statistical classification of diseases and related health problems codes (ICD) and process keys (OPS) for extracorporeal membrane oxygenation (ECMO) types, acute respiratory distress syndrome (ARDS) and hospital mortality were used. RESULTS: In total, 45,647 hospitalized patients treated with ECLS were analysed. In Germany, 231 hospitals provided ECLS therapy, with a median of 4 VV-ECMO and 9 VA-ECMO in 2018. Overall hospital mortality remained higher than predicted in comparison to the values reported in the literature. The number of VV-ECMO cases increased by 236% from 825 in 2007 to 2768 in 2018. ARDS was the main indication for VV-ECMO in only 33% of the patients in the past, but that proportion increased to 60% in 2018. VA-ECMO support is of minor importance in the treatment of ARDS in Germany. The age distribution of patients undergoing ECLS has shifted towards an older population. In 2018, the hospital mortality decreased in VV-ECMO patients and VV-ECMO patients with ARDS to 53.9% (n = 1493) and 54.4% (n = 926), respectively. CONCLUSIONS: ARDS is a severe disease with a high mortality rate despite ECLS therapy. Although endpoints and timing of the evaluations differed from those of the CESAR and EOLIA studies and the Extracorporeal Life Support Organization (ELSO) Registry, the reported mortality in these studies was lower than in the present analysis. Further prospective analyses are necessary to evaluate outcomes in ECMO therapy at the centre volume level. BioMed Central 2021-01-28 /pmc/articles/PMC7841040/ /pubmed/33509228 http://dx.doi.org/10.1186/s13054-021-03463-2 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Friedrichson, Benjamin Mutlak, Haitham Zacharowski, Kai Piekarski, Florian Insight into ECMO, mortality and ARDS: a nationwide analysis of 45,647 ECMO runs |
title | Insight into ECMO, mortality and ARDS: a nationwide analysis of 45,647 ECMO runs |
title_full | Insight into ECMO, mortality and ARDS: a nationwide analysis of 45,647 ECMO runs |
title_fullStr | Insight into ECMO, mortality and ARDS: a nationwide analysis of 45,647 ECMO runs |
title_full_unstemmed | Insight into ECMO, mortality and ARDS: a nationwide analysis of 45,647 ECMO runs |
title_short | Insight into ECMO, mortality and ARDS: a nationwide analysis of 45,647 ECMO runs |
title_sort | insight into ecmo, mortality and ards: a nationwide analysis of 45,647 ecmo runs |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841040/ https://www.ncbi.nlm.nih.gov/pubmed/33509228 http://dx.doi.org/10.1186/s13054-021-03463-2 |
work_keys_str_mv | AT friedrichsonbenjamin insightintoecmomortalityandardsanationwideanalysisof45647ecmoruns AT mutlakhaitham insightintoecmomortalityandardsanationwideanalysisof45647ecmoruns AT zacharowskikai insightintoecmomortalityandardsanationwideanalysisof45647ecmoruns AT piekarskiflorian insightintoecmomortalityandardsanationwideanalysisof45647ecmoruns |